Assignee
argenx BV
BE·20 granted patents·37 pending applications·29 citations·filing 2017–2025
Top patents by PatentIndex Score
57 records- 0192US11505585B2FcRn antagonists and methods of useargenx BV·Filed 2017·Granted Nov 22, 2022·7 cites·10 claims
- 0290US12344678B2FcRn/HSA binding molecules and methods of useargenx BV·Filed 2024·Granted Jul 1, 2025·3 cites·14 claims
- 0390US2026042856A1Antibodies to cd70argenx BV·Filed 2025·Application pending·0 cites
- 0488US12240875B2Use of FCRN antagonists for treatment of generalized myasthenia gravisargenx BV·Filed 2018·Granted Mar 4, 2025·3 cites·21 claims
- 0588US11591388B2Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administrationargenx BV·Filed 2020·Granted Feb 28, 2023·6 cites·21 claims
- 0685US12202900B2Compositions and methods for treating immune thrombocytopeniaargenx BV·Filed 2019·Granted Jan 21, 2025·4 cites·14 claims
- 0785US11712468B2CD70 combination therapyargenx BV·Filed 2019·Granted Aug 1, 2023·3 cites·36 claims
- 0883US11434298B2Antibodies to CD70argenx BV·Filed 2019·Granted Sep 6, 2022·1 cites·11 claims
- 0981US2024002484A1ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2b AND METHODS OF USEargenx BV·Filed 2023·Application pending·0 cites
- 1081US2024158492A1Il-6 binding moleculesargenx BV·Filed 2023·Application pending·0 cites
- 1181US2023265201A1Antibodies to cd70argenx BV·Filed 2022·Application pending·0 cites
- 1280US12403175B2Methods for treating pemphigus disordersargenx BV·Filed 2021·Granted Sep 2, 2025·1 cites·21 claims
- 1379US11708403B2Antibodies to human complement factor C2B and methods of useargenx BV·Filed 2022·Granted Jul 25, 2023·0 cites·14 claims
- 1478US12565538B2FCRN/antigen-binding molecules and methods of useargenx BV·Filed 2025·Granted Mar 3, 2026·0 cites·11 claims
- 1578US11591386B2Antibodies to human complement C2Bargenx BV·Filed 2021·Granted Feb 28, 2023·0 cites·20 claims
- 1676US2025388700A1Variant fc regionsargenx BV·Filed 2025·Application pending·0 cites
- 1776US2025388699A1Variant fc regionsargenx BV·Filed 2025·Application pending·0 cites
- 1875US11827701B2IL-6 binding moleculesargenx BV·Filed 2021·Granted Nov 28, 2023·0 cites·18 claims
- 1975US2024368311A1Bispecific antigen binding constructargenx BV·Filed 2024·Application pending·0 cites
- 2075US2025059262A1Method of preparing ph-dependent antibodiesargenx BV·Filed 2024·Application pending·0 cites
- 2173US2025215090A1Compositions and methods for treating immune thrombocytopeniaargenx BV·Filed 2024·Application pending·0 cites
- 2271US2026015415A1Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administrationargenx BV·Filed 2025·Application pending·0 cites
- 2371US2024026010A1Galectin-10 antibodiesargenx BV·Filed 2023·Application pending·0 cites
- 2471US2024033353A1Cd70 combination therapyargenx BV·Filed 2023·Application pending·0 cites
- 2571US2025382388A1Fcrn/hsa binding molecules and methods of useargenx BV·Filed 2025·Application pending·0 cites
- 2670US11530271B2CD70 combination therapyargenx BV·Filed 2019·Granted Dec 20, 2022·1 cites·24 claims
- 2770US2025122288A1Fcrn binding molecules and methods of useargenx BV·Filed 2024·Application pending·0 cites
- 2870US2022275035A1Fcrn antagonists and methods of useargenx BV·Filed 2022·Application pending·0 cites
- 2969US11447544B2Anti-IL-22R antibodiesargenx BV·Filed 2019·Granted Sep 20, 2022·0 cites·26 claims
- 3068US2024352138A1Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13rargenx BV·Filed 2024·Application pending·0 cites
- 3168US2025051453A1Methods for treating bullous pemphigoid using fcrn antagonistsargenx BV·Filed 2024·Application pending·0 cites
- 3267US12180293B2CD70 combination therapyargenx BV·Filed 2022·Granted Dec 31, 2024·0 cites·18 claims
- 3367US2023357382A1Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administrationargenx BV·Filed 2023·Application pending·0 cites
- 3464US2026008854A1Methods for vaccination of a subject treated with an fcrn antagonistargenx BV·Filed 2025·Application pending·0 cites
- 3563US11649295B2Asymmetric multispecific antibodiesargenx BV·Filed 2019·Granted May 16, 2023·0 cites·16 claims
- 3663US2024369467A1Methods for treating patients with an autoantibody-mediated diseaseargenx BV·Filed 2024·Application pending·0 cites
- 3761US12071486B2Bispecific antigen binding constructargenx BV·Filed 2018·Granted Aug 27, 2024·0 cites·4 claims
- 3861US2025152707A1Cd70 combination therapyargenx BV·Filed 2025·Application pending·0 cites
- 3961US2024325528A1Subcutaneous unit dosage formsargenx BV·Filed 2024·Application pending·0 cites
- 4060US2025101111A1Fcrn antagonists and methods of useargenx BV·Filed 2024·Application pending·0 cites
- 4160US2025051477A1Anti-musk antibodies for use in treating neuromuscular disordersargenx BV·Filed 2024·Application pending·0 cites
- 4260US2025179133A1Use of fcrn antagonists for treatment of generalized myasthenia gravisargenx BV·Filed 2025·Application pending·0 cites
- 4359US2025188190A1In utero treatment of a fetus having genetic disease/neuromuscular diseaseargenx BV·Filed 2024·Application pending·0 cites
- 4458US2024182590A1Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitorargenx BV·Filed 2023·Application pending·0 cites
- 4558US2025388679A1Subcutaneous fcrn antagonist formulations and methods of use thereofargenx BV·Filed 2025·Application pending·0 cites
- 4658US2024109960A1Anti-il-9 antibodies and methods of use thereofargenx BV·Filed 2023·Application pending·0 cites
- 4757US2025084171A1Methods for treating myositis using fcrn antagonistsargenx BV·Filed 2024·Application pending·0 cites
- 4856US12060413B2Method of preparing pH-dependent antibodiesargenx BV·Filed 2018·Granted Aug 13, 2024·0 cites·33 claims
- 4956US2025059285A1Galectin-10 antibodiesargenx BV·Filed 2024·Application pending·0 cites
- 5055US12030949B2Multispecific antibodies against IL-5 and IL-4Rargenx BV·Filed 2019·Granted Jul 9, 2024·0 cites·20 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when argenx BV files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →